Point Biopharma slumps 35% on license deal with Lantheus for cancer drugs

Nov. 14, 2022 10:57 AM ETLantheus Holdings, Inc. (LNTH), PNTBy: Ravikash, SA News Editor1 Comment

forex charts

Adam Smigielski

Point Biopharma Global's (NASDAQ:PNT) stock fell ~35% on Monday after the company said it was selling licensing rights to radiopharmaceutical cancer drug candidates PNT2002 and PNT2003 to Lantheus (NASDAQ:LNTH).

Upon completion, Lantheus will get exclusive worldwide rights, excluding certain territories, for the drug candidates. In

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.